JUPITER NEUROSCIENCES, INC.

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company focused on developing treatments that utilize an enhanced oral resveratrol formulation to address neuroinflammation, central nervous system disorders, and rare diseases. Its proprietary platform product, JOTROL, delivers resveratrol using micellar technology designed to enhance absorption and bioavailability. The company operates through two main business segments: pharmaceutical operations targeting therapeutic indications such as Parkinson's disease, and consumer products consisting of premium nutritional supplements sold under the Nugevia brand name. The initial Nugevia wellness product line comprises three formulations—GLO, MND, and PWR—marketed directly to consumers for cellular health, cognitive support, and mitochondrial performance.

The company maintains its principal executive offices and headquarters in Jupiter, Florida. Its product operations serve consumers in the United States with planned international reach, supported by regional business development agreements across Southeast Asia, including China, Malaysia, and Singapore. Clinical trial supplies are manufactured in Florida, with underlying technology developed alongside a partner based in Germany.

Summary of the business section of Jupiter Neurosciences's latest annual report, written by StockData.

“As of December 31, 2025, we had a total of five full-time employees, two full-time consultants, three part-time consultants, and our six Scientific Advisory Board members.”